{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:50Z","timestamp":1790959370187,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GO565\/17-1"],"award-info":[{"award-number":["GO565\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejpb.2015.02.027","type":"journal-article","created":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T16:06:17Z","timestamp":1425744377000},"page":"294-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"PB","title":["Nanoparticles for the treatment of ocular neovascularizations"],"prefix":"10.1016","volume":"95","author":[{"given":"Robert","family":"Hennig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Goepferich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.02.027_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0015","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/eye.2010.122","article-title":"Causes of blind and partial sight certifications in England and Wales: April 2007\u2013March 2008","volume":"24","author":"Bunce","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ejpb.2015.02.027_b0020","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.02.027_b0030","series-title":"Diabetic Retinopathy","article-title":"Proliferative diabetic retinopathy","author":"Danis","year":"2008"},{"key":"10.1016\/j.ejpb.2015.02.027_b0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","article-title":"Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex","volume":"33","author":"Bhutto","year":"2012","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0014-5793(01)02110-X","article-title":"Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization","volume":"489","author":"Gao","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejpb.2015.02.027_b0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrn1176","article-title":"PEDF: a multifaceted neurotrophic factor","volume":"4","author":"Tombran-Tink","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: role of the HIF system","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvs136","article-title":"Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases","volume":"153","author":"Shibuya","year":"2013","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejpb.2015.02.027_b0060","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.02.027_b0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0070","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual function: evidence for a survival role on m\u00fcller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0075","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1167\/iovs.11-8353","article-title":"Expression and role of VEGF in the adult retinal pigment epithelium","volume":"52","author":"Ford","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0080","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ajo.2007.03.007","article-title":"Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab","volume":"143","author":"Peters","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0085","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0090","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.preteyeres.2010.08.002","article-title":"Applications of nanoparticles in ophthalmology","volume":"29","author":"Diebold","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0095","series-title":"Age-related Macular Degeneration Diagnosis and Treatment","article-title":"Management of neovascular AMD","author":"Penha","year":"2011"},{"key":"10.1016\/j.ejpb.2015.02.027_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":"Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0105","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1167\/iovs.02-1068","article-title":"Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles","volume":"44","author":"Bourges","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10633-011-9305-y","article-title":"The pathogenesis of early retinal changes of diabetic retinopathy","volume":"124","author":"Arden","year":"2012","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0115","first-page":"26","article-title":"Epidemiology of age-related macular degeneration","volume":"5","author":"Hawkins","year":"1999","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2015.02.027_b0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population","volume":"129","author":"Klein","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0125","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ejpb.2015.02.027_b0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2004.07.004","article-title":"Pathogenesis of age-related macular degeneration","volume":"10","author":"Tezel","year":"2004","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0135","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMra062326","article-title":"Age-related macular degeneration","volume":"355","author":"de Jong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0140","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.02.027_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20120588","article-title":"Advances in our understanding of diabetic retinopathy","volume":"125","author":"Stitt","year":"2013","journal-title":"Clin. Sci."},{"issue":"2010","key":"10.1016\/j.ejpb.2015.02.027_b0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejpb.2015.02.027_b0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejpb.2015.02.027_b0160","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/eye.2014.13","article-title":"A review of anti-VEGF agents for proliferative diabetic retinopathy","volume":"28","author":"Osaadon","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ejpb.2015.02.027_b0165","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICB.0b013e3181578dd8","article-title":"Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy","volume":"3","author":"Torres-Soriano","year":"2009","journal-title":"Retin. Cases Brief Rep."},{"key":"10.1016\/j.ejpb.2015.02.027_b0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(08)60074-4","article-title":"Epidemiology and causes of preterm birth","volume":"371","author":"Goldenberg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.02.027_b0180","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/archophthalmol.2009.244","article-title":"Incidence of retinopathy of prematurity in infants born before 27 weeks\u2019 gestation in Sweden","volume":"127","author":"Austeng","year":"2009","journal-title":"Arch. Ophthalmol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejpb.2015.02.027_b0185","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1038\/sj.jp.7211475","article-title":"Oxygen and retinopathy of prematurity","volume":"26","author":"Saugstad","year":"2006","journal-title":"J. Perinatol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejpb.2015.02.027_b0195","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.13-11948","article-title":"Anti-VEGF in retinopathy of prematurity, need to titrate","volume":"54","author":"Vavvas","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0210","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0215","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3129\/i07-153","article-title":"Burden of illness of neovascular age-related macular degeneration in Canada","volume":"42","author":"Cruess","year":"2007","journal-title":"Can. J. Ophthalmol."},{"issue":"Pt 2","key":"10.1016\/j.ejpb.2015.02.027_b0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/eye.1991.32","article-title":"Temperature modulating action of choroidal blood flow","volume":"5","author":"Parver","year":"1991","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ejpb.2015.02.027_b0225","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","article-title":"The multifunctional choroid","volume":"29","author":"Nickla","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-4835(73)90185-1","article-title":"Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (Macaca irus): a study with radioactively labelled microspheres including flow determinations in brain and some other tissues","volume":"15","author":"Alm","year":"1973","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0235","series-title":"Retinal Vascular Disease","article-title":"Retinal blood flow","author":"lSchmetterer","year":"2007"},{"key":"10.1016\/j.ejpb.2015.02.027_b0240","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0161-6420(95)30974-8","article-title":"Ocular blood flow velocity in age-related macular degeneration","volume":"102","author":"Friedman","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0245","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-4835(91)90256-E","article-title":"Choroidal blood flow in diabetic retinopathy","volume":"52","author":"Langham","year":"1991","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0250","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0255","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2015.02.027_b0260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2015.02.027_b0265","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.02.027_b0270","first-page":"2690","article-title":"Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization","volume":"40","author":"Yasukawa","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archopht.118.1.78","article-title":"Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization","volume":"118","author":"Tolentino","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0280","first-page":"2664","article-title":"Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat","volume":"42","author":"Kamizuru","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0285","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","article-title":"Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model","volume":"153","author":"Tobe","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2010.03.016","article-title":"Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection","volume":"150","author":"Kohno","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0295","first-page":"204","article-title":"Newly-formed subretinal vessels. Fine structure and fluorescein leakage","volume":"27","author":"Miller","year":"1986","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/path.1711240104","article-title":"The effects of chronic cervical lymphostasis on regions drained by lymphatics and by prelymphatics","volume":"124","author":"Casley-Smith","year":"1978","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0305","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.027_b0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.027_b0315","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nmat3792","article-title":"Strategies for advancing cancer nanomedicine","volume":"12","author":"Chauhan","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ejpb.2015.02.027_b0320","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nano.2012.07.002","article-title":"Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure","volume":"9","author":"Torosean","year":"2013","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0325","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure \u2013 an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.02.027_b0330","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1002192829817","article-title":"Mechanisms of fluid accumulation in retinal edema","volume":"97","author":"Marmor","year":"1999","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0335","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0340","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mla.2010.07.003","article-title":"Current indications for ocular photodynamic therapy \u2013 a review of the literature and two case reports","volume":"25","author":"Berger","year":"2010","journal-title":"Med. Laser Appl."},{"key":"10.1016\/j.ejpb.2015.02.027_b0345","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.drudis.2013.04.003","article-title":"Current status of liposomal porphyrinoid photosensitizers","volume":"18","author":"Skupin-Mrugalska","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.02.027_b0350","first-page":"13","article-title":"Drug release characteristics of lipid based benzoporphyrin derivative","volume":"6","author":"Chowdhary","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0355","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(00)00158-2","article-title":"Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration","volume":"45","author":"Schmidt-Erfurth","year":"2000","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0360","first-page":"CD002030","article-title":"Photodynamic therapy for neovascular age-related macular degeneration","author":"Wormald","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2015.02.027_b0365","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1021\/nl051679d","article-title":"Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer","volume":"5","author":"Ideta","year":"2005","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2015.02.027_b0370","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/anie.200461603","article-title":"Supramolecular nanocarrier of anionic dendrimer porphyrins with cationic block copolymers modified with polyethylene glycol to enhance intracellular photodynamic efficacy","volume":"44","author":"Jang","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.02.027_b0375","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1167\/iovs.02-1115","article-title":"Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor","volume":"44","author":"Schmidt-Erfurth","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0380","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1167\/iovs.13-13068","article-title":"Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib","volume":"54","author":"Wang","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0385","first-page":"54","article-title":"Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes","volume":"19","author":"Gross","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2015.02.027_b0390","first-page":"6132","article-title":"Increased exposure of anionic phospholipids on the surface of tumor blood vessels","volume":"62","author":"Ran","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0395","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1172\/JCI965","article-title":"Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice","volume":"101","author":"Thurston","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2015.02.027_b0400","first-page":"1045","article-title":"In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes","volume":"18","author":"Hua","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2015.02.027_b0405","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin targeted therapeutics","volume":"1","author":"Millard","year":"2011","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2015.02.027_b0410","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0070-2153(04)64009-9","article-title":"Integrins and angiogenesis","volume":"64","author":"Stupack","year":"2004","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0415","first-page":"3466","article-title":"Immunolocalization of integrins in the human retina","volume":"35","author":"Brem","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0420","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/gt.2008.185","article-title":"Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV","volume":"16","author":"Singh","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0425","doi-asserted-by":"crossref","first-page":"e18864","DOI":"10.1371\/journal.pone.0018864","article-title":"Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization","volume":"6","author":"Salehi-Had","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0430","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1073\/pnas.1220281110","article-title":"Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application","volume":"110","author":"Pollinger","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.02.027_b0435","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.ejpb.2015.02.027_b0440","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","article-title":"Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases","volume":"93","author":"Friedlander","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.02.027_b0445","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2014.07.062","article-title":"Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation","volume":"194C","author":"Hennig","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.027_b0450","doi-asserted-by":"crossref","first-page":"a006478","DOI":"10.1101\/cshperspect.a006478","article-title":"\u0391V integrins in angiogenesis and cancer","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0455","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nm0596-529","article-title":"Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization","volume":"2","author":"Hammes","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0460","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/nn305958y","article-title":"Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration","volume":"7","author":"Luo","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.02.027_b0465","first-page":"1049","article-title":"Arg-Gly-Asp (RGD) peptide ameliorates carbon tetrachloride-induced liver fibrosis via inhibition of collagen production and acceleration of collagenase activity","volume":"14","author":"Kotoh","year":"2004","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0470","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1167\/iovs.04-1172","article-title":"Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo","volume":"46","author":"Singh","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0475","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejpb.2015.02.027_b0480","first-page":"124","article-title":"Nanoparticles for gene delivery to retinal pigment epithelial cells","volume":"11","author":"Bejjani","year":"2005","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2015.02.027_b0485","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.04.023","article-title":"Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells","volume":"360","author":"del Pozo-Rodr\u00edguez","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.027_b0490","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1167\/iovs.10-5891","article-title":"A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model","volume":"52","author":"Liu","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0495","article-title":"Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells","author":"Mastorakos","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2015.02.027_b0500","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.nano.2008.06.003","article-title":"Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium","volume":"4","author":"Prow","year":"2008","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0505","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pone.0000038","article-title":"Efficient non-viral ocular gene transfer with compacted DNA nanoparticles","volume":"1","author":"Farjo","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0510","doi-asserted-by":"crossref","first-page":"9483","DOI":"10.1016\/j.biomaterials.2011.08.062","article-title":"Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells","volume":"32","author":"Koirala","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.02.027_b0515","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/cmdc.201300371","article-title":"Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery","volume":"9","author":"Mitra","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejpb.2015.02.027_b0520","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/bjo.64.7.537","article-title":"Ultrastructure of fenestrations in endothelial choriocapillaries of the rabbit \u2013 a freeze-fracturing study","volume":"64","author":"Melamed","year":"1980","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.027_b0530","first-page":"2970","article-title":"The effect of age on the macromolecular permeability of human Bruch\u2019s membrane","volume":"42","author":"Moore","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0535","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.exer.2011.10.016","article-title":"Passage of low-density lipoproteins through Bruch\u2019s membrane and choroid","volume":"93","author":"Cankova","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0540","doi-asserted-by":"crossref","first-page":"505101","DOI":"10.1088\/0957-4484\/20\/50\/505101","article-title":"Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity","volume":"20","author":"Kim","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0545","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1083\/jcb.86.2.688","article-title":"Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion","volume":"86","author":"Kanwar","year":"1980","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0550","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/ki.1995.178","article-title":"Charge selectivity in kidney ultrafiltration","volume":"47","author":"Comper","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejpb.2015.02.027_b0555","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1083\/jcb.67.3.638","article-title":"Role of molecular charge in glomerular permeability. Tracer studies with cationized ferritins","volume":"67","author":"Rennke","year":"1975","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0560","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1167\/iovs.14-14126","article-title":"Age-dependent changes in heparan sulfate in human Bruch\u2019s membrane: implications for age-related macular degeneration","volume":"55","author":"Keenan","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0565","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of quantum dots","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"Pt 2","key":"10.1016\/j.ejpb.2015.02.027_b0570","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/eye.1987.35","article-title":"The influence of age on some ocular basement membranes","volume":"1","author":"Fisher","year":"1987","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ejpb.2015.02.027_b0575","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","article-title":"Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies","volume":"48","author":"Ambati","year":"2003","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0580","first-page":"265","article-title":"Accumulation of cholesterol with age in human Bruch\u2019s membrane","volume":"42","author":"Curcio","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0585","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0039-6257(87)90115-9","article-title":"Pathophysiology of age-related macular degeneration","volume":"31","author":"Young","year":"1987","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0590","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1242\/jcs.006361","article-title":"Tetraspanin CD81 is required for the alpha v beta5-integrin-dependent particle-binding step of RPE phagocytosis","volume":"120","author":"Chang","year":"2007","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0595","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev.biochem.74.050304.091637","article-title":"Gene therapy: twenty-first century medicine","volume":"74","author":"Verma","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejpb.2015.02.027_b0600","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.gt.3302812","article-title":"Gene therapy progress and prospects: the eye","volume":"13","author":"Bainbridge","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0605","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.gt.3302030","article-title":"Immune response following intraocular delivery of recombinant viral vectors","volume":"10","author":"Bennett","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0610","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.exer.2004.06.023","article-title":"Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide","volume":"79","author":"Marano","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0615","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/sj.gt.3302579","article-title":"Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity","volume":"12","author":"Marano","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0620","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.02.027_b0625","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nm0398-365","article-title":"Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses","volume":"4","author":"Hedley","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2015.02.027_b0630","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/db08-1327","article-title":"Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage","volume":"58","author":"Park","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2015.02.027_b0635","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/gt.2009.158","article-title":"Inhibitory efficacy of hypoxia-inducible factor 1alpha short hairpin RNA plasmid DNA-loaded poly(d,l-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model","volume":"17","author":"Zhang","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0640","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0645","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jop.2010.0158","article-title":"Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model","volume":"27","author":"Pan","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0655","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/jop.2007.0002","article-title":"Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model","volume":"23","author":"Xu","year":"2007","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0660","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2012.05.025","article-title":"Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide","volume":"434","author":"Kadam","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.02.027_b0665","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","article-title":"Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression","volume":"44","author":"Kompella","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0670","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/138945011794182746","article-title":"Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration","volume":"12","author":"Becerra","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejpb.2015.02.027_b0675","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.biomaterials.2011.01.003","article-title":"Anti-Flt1 peptide\u2013hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy","volume":"32","author":"Oh","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.02.027_b0680","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bcp.2006.02.009","article-title":"Molecular targets of dietary agents for prevention and therapy of cancer","volume":"71","author":"Aggarwal","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0685","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.actbio.2012.07.016","article-title":"Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization","volume":"8","author":"Kim","year":"2012","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2015.02.027_b0690","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2009.10.031","article-title":"Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats","volume":"142","author":"Kim","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.027_b0695","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.0812801106","article-title":"Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells","volume":"106","author":"Lee","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.02.027_b0700","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jconrel.2013.10.008","article-title":"Sustained delivery of a HIF-1 antagonist for ocular neovascularization","volume":"172","author":"Iwase","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.02.027_b0705","first-page":"32","article-title":"Oxidative damage and age-related macular degeneration","volume":"5","author":"Winkler","year":"1999","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2015.02.027_b0710","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ophtha.2011.04.029","article-title":"Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors","volume":"118","author":"Seddon","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.02.027_b0715","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.1996.03540140029022","article-title":"A prospective study of cigarette smoking and age-related macular degeneration in women","volume":"276","author":"Seddon","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2015.02.027_b0720","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0725","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1167\/iovs.09-4478","article-title":"Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture","volume":"51","author":"Hollyfield","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.02.027_b0730","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1562\/LE-03-17.1","article-title":"Mitochondria-derived reactive oxygen species mediate blue light-induced death of retinal pigment epithelial cells","volume":"79","author":"King","year":"2004","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0735","doi-asserted-by":"crossref","first-page":"243110","DOI":"10.1063\/1.2210795","article-title":"Role of trivalent La and Nd dopants in lattice distortion and oxygen vacancy generation in cerium oxide nanoparticles","volume":"88","author":"Patil","year":"2006","journal-title":"Appl. Phys. Lett."},{"issue":"2008","key":"10.1016\/j.ejpb.2015.02.027_b0740","first-page":"33","article-title":"Nanoceria as antioxidant: synthesis and biomedical applications","volume":"60","author":"Karakoti","year":"1989","journal-title":"JOM"},{"key":"10.1016\/j.ejpb.2015.02.027_b0745","doi-asserted-by":"crossref","first-page":"e16733","DOI":"10.1371\/journal.pone.0016733","article-title":"Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0750","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nnano.2006.91","article-title":"Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides","volume":"1","author":"Chen","year":"2006","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0755","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.exer.2013.08.003","article-title":"Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice","volume":"116","author":"Kyosseva","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0760","doi-asserted-by":"crossref","first-page":"e58431","DOI":"10.1371\/journal.pone.0058431","article-title":"Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0765","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.biomaterials.2013.10.022","article-title":"Sustained inhibition of neovascularization in vldlr\u2212\/\u2212 mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38\/JNK-NF-\u03baB pathway","volume":"35","author":"Cai","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.02.027_b0770","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/rheumatology\/41.12.1346","article-title":"Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review","volume":"41","author":"Pincus","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejpb.2015.02.027_b0775","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1021\/nl0483789","article-title":"Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells","volume":"4","author":"Bhattacharya","year":"2004","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2015.02.027_b0780","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1158\/1078-0432.CCR-04-2482","article-title":"Antiangiogenic properties of gold nanoparticles","volume":"11","author":"Mukherjee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0785","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.exer.2010.09.003","article-title":"Gold nanoparticles downregulate VEGF-and IL-1\u03b2-induced cell proliferation through Src kinase in retinal pigment epithelial cells","volume":"91","author":"Karthikeyan","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.02.027_b0790","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1097-2765(00)80221-X","article-title":"Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability","volume":"4","author":"Eliceiri","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejpb.2015.02.027_b0795","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.colsurfb.2009.04.025","article-title":"Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells","volume":"73","author":"Kalishwaralal","year":"2009","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.ejpb.2015.02.027_b0800","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.nano.2011.09.003","article-title":"Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor","volume":"8","author":"Jo","year":"2012","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0805","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1039\/c3nr04363k","article-title":"Cuprous oxide nanoparticles inhibit angiogenesis via down regulation of VEGFR2 expression","volume":"6","author":"Song","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2015.02.027_b0810","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2010.11.030","article-title":"The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.02.027_b0815","article-title":"Intraocular biocompatibility of gold-nanoparticles","volume":"02","author":"babAmmar","year":"2013","journal-title":"J. Nanomater. Mol. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0820","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/IAE.0b013e3180dc9360","article-title":"Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model","volume":"28","author":"Bakri","year":"2008","journal-title":"Retina (Philadelphia, PA)"},{"key":"10.1016\/j.ejpb.2015.02.027_b0825","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.nano.2014.02.007","article-title":"Anti-angiogenic effect of bare titanium dioxide nanoparticles on pathologic neovascularization without unbearable toxicity","volume":"10","author":"Jo","year":"2014","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.02.027_b0830","doi-asserted-by":"crossref","first-page":"e105359","DOI":"10.1371\/journal.pone.0105359","article-title":"Silver and gold nanoparticles exposure to in vitro cultured retina \u2013 studies on nanoparticle internalization, apoptosis, oxidative stress, glial- and microglial activity","volume":"9","author":"S\u00f6derstjerna","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0835","doi-asserted-by":"crossref","first-page":"e28560","DOI":"10.1371\/journal.pone.0028560","article-title":"Gene transfer using micellar nanovectors inhibits choroidal neovascularization in vivo","volume":"6","author":"Iriyama","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.027_b0840","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/jop.2008.0119","article-title":"Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4","volume":"25","author":"Ma","year":"2009","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.02.027_b0845","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.1016\/S0021-9258(18)53062-3","article-title":"Covalently immobilized laminin peptide Tyr-Ile-Gly-Ser-Arg (YIGSR) supports cell spreading and co-localization of the 67-kilodalton laminin receptor with alpha-actinin and vinculin","volume":"268","author":"Massia","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2015.02.027_b0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012515","article-title":"Broad spectrum antiangiogenic treatment for ocular neovascular diseases","volume":"5","author":"Benny","year":"2010","journal-title":"PLoS ONE"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T17:19:43Z","timestamp":1651425583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":170,"alternative-id":["S0939641115001095"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.027","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles for the treatment of ocular neovascularizations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}